NOVOGEN LTD
Known title: 10% OwnerCIK: 0001075880
Associated companies
Transaction History
| KZIA | ▼ Sell | Other | 17,837,246 | $0 | 12/3/2012 | View on chart |
| KZIA | ▼ Sell | Other | 4,827,000 | $0 | 11/20/2012 | View on chart |
| KZIA | ▼ Sell | Other | 4,494,377 | $4.0M | 5/11/2012 | View on chart |
| KZIA | ▲ Buy | Grant | 1,941,747 | $2.0M | 12/29/2011 | View on chart |
| KZIA | ▲ Buy | Grant | 1,333,333 | $2.0M | 9/30/2011 | View on chart |
| KZIA | ▲ Buy | Open Market | 2,908,295 | $6.3M | 7/28/2008 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Kazia Therapeutics Doses First Patient in Phase 1b/2a Paxalisib Trial
Kazia Therapeutics has started its Phase 1b/2a study of Paxalisib for rare seizure disorders, dosing the first patient in collaboration with Sovargen. This milestone moves the drug into early human testing and provides the first safety data for the compound. The company will monitor results to decide on next steps in development.
Kazia Therapeutics Doses First Patient in Phase 1b/2a Paxalisib Trial. Kazia Therapeutics has started its Phase 1b/2a study of Paxalisib for rare seizure disorders, dosing the first patient in collaboration with Sovargen. This milestone moves the drug into early human testing and provides the first safety data for the compound. The company will monitor results to decide on next steps in development.